Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: An open-label phase 1b study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Guo, Jun ^a   Huang, Yiran ^b   Zhang, Xu ^c   Zhou, Fangjian ^d   Sun, Yinghao ^e   Qin, Shukui ^f   Ye, Zhangqun ^g   Wang, Hui ^h   Jappe, Annette ⁱ   Straub, Patrick ⁱ   Pirotta, Nicoletta ⁱ   Gogov, Sven ⁱ  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f Nanjing Bayi Hospital   (China)

^g Tongji Hospital   (China)

^h Beijing Baiao Pharmaceuticals Co Ltd   (China)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sorafenib; Sunitinib

Indexed keywords

EVEROLIMUS; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE METASTASIS; CHINESE; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOPENIA; LIVER METASTASIS; LUNG DISEASE; LUNG FIBROSIS; LUNG INFECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NONINFECTIOUS PNEUMONITIS; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RESPIRATORY FAILURE; RETROPERITONEAL CANCER; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CHINA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875198604     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-136     Document Type: Article

References (32)

1. American Cancer Society Cancer Facts and Figures 2012 2012, 1-66. Atlanta, GA: American Cancer Society, American Cancer Society.
2. International Agency for Research on Cancer Globocan 2008 fast stats China, [http://globocan.iarc.fr/factsheet.asp], International Agency for Research on Cancer.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005, 14:243-250.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490. 10.1056/NEJMra043172, 16339096.
5. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, . for the AVOREN Trial Investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111. 10.1016/S0140-6736(07)61904-7, 18156031, for the AVOREN Trial Investigators.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, . for the TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530, for the TARGET Study Group.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143. 10.1200/JCO.2009.26.5561, 2860433, 20368558.
9. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068. 10.1200/JCO.2009.23.9764, 20100962.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265. 10.1002/cncr.25219, 20549832.
11. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939. 10.1016/S0140-6736(11)61613-9, 22056247.
12. National Comprehensive Cancer Network, Inc The NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer V.2.2012 [http://www.nccn.org], National Comprehensive Cancer Network, Inc.
13. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23:vii65-vii71. 10.1093/annonc/mds227, 22997456.
14. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406. 10.1016/j.eururo.2010.06.032, 20633979.
15. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773. 10.1016/j.ejca.2008.12.010, 19157861.
16. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348. 10.1038/nrc1362, 15122205.
17. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822. 10.1074/jbc.270.2.815, 7822316.
18. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi J-F, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 2011, 6:323-338. 10.1517/17460441.2011.558079, 22647206.
19. Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011, 6:214-221. 10.2174/157488411797189433, 21827395.
20. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
21. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610. 10.1200/JCO.2007.14.5482, 18332469.
22. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446. 10.1002/cncr.24280, 19306412.
23. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2007, 25(Suppl):5107.
24. Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data form the phase 3 RECORD-1 trial. BMC Cancer 2012, 12.
25. Stein A, Carter A, Hollaender N, Motzer R, Sarr C. Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): a dynamic tumor model of the RECORD-1 phase III trial. J Clin Oncol 2011, 29(Suppl). abstr 4602. Presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7; Chicago, Illinois.
26. Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R. Two dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematold Oncol 2011, 4:3.
27. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events V3.0 (CTCAE) [http://ctep.cancer.gov], Cancer Therapy Evaluation Program.
28. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, . for the RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228, for the RECORD-1 Study Group.
29. Porta C, Ostanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011, 47:1287-1298. 10.1016/j.ejca.2011.02.014, 21481584.
30. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(suppl 2):32-44.
31. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182:396-403. 10.1164/rccm.200911-1720OC, 20194812.
32. Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011, 41:17-24. 10.1093/jjco/hyq166, 3012894, 20965941.